Lee and colleagues characterized the terpenoid sargachromanol (119) compound, purified from the brown alga Sargassum siliquastrum, finding that it potently inhibited AChE via a mixed reversible inhibition, suggesting that it binds to both an active site and a non-catalytic site of AChE, in turn suggesting potential therapeutic development for the treatment of AD [139]. Here, ACHE is linked to Alzheimer disease.